CTA30X UCAR-T

DB24819InvestigationalCell transplant therapies

CTA30X UCAR-T is a biologic drug. CTA30X UCAR-T is under investigation in clinical trial NCT05015972 (UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies).

Mechanism: Pharmacologically active on B-lymphocyte antigen CD19
Curator reviewed
Code names: CTA30X

Resolves to

Targets

P15391CD19

What you can answer from here — as of June 28, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with CTA30X UCAR-T, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account